

Garry Walsh

Asthmatic and Allergic Inflammation
Group, School of Medicine,
University of Aberdeen, UK

Welcome to the first issue of *Therapeutics and Clinical Risk Management* – a new international peer-reviewed journal. As the title suggests, the journal will publish original research and review articles on the evidence and opinion behind new and existing therapies. A further aim will be to define the usage of these therapies in terms of ultimate uptake and acceptance by the patient and healthcare professional. This is an area that to date has been somewhat neglected, and Dove Medical Press are to be congratulated for the launch of a new title that addresses these vital issues in an era when evidence-based medicine is becoming ever more important. The remit of the journal will of necessity be a broad one and, in this respect, represents a considerable challenge to all involved.

This first issue comprises two diverse but important review articles and some excellent original research from authors based worldwide. The original research papers encompass a broad spectrum covering areas as varied as compliance in asthma therapy, anticonvulsive therapy in pregnancy, issues associated with anti-infective therapy, drug-related problems associated with old age or polypharmacy, aortic aneurysm repair, GP practice prescribing rates, and the use of anti-inflammatory therapy by physiotherapists. This issue reflects the overall remit of *Therapeutics and Clinical Risk Management*, and I hope the journal becomes an important resource for health professionals in the 21st century. As well as review articles and original research, future issues will include expert opinion, single case reports, and letters to the editor. It only remains for me to thank my co-editors, the members of our editorial board, reviewers, authors, and Dove Medical Press for their tremendous help in preparing this inaugural issue.

